Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Engineered Mesenchymal Stem Cell/Nanomedicine Spheroid as an Active Drug Delivery Platform for Combinational Glioblastoma Therapy.

Suryaprakash S, Lao YH, Cho HY, Li M, Ji HY, Shao D, Hu H, Quek CH, Huang D, Mintz RL, Bagó JR, Hingtgen SD, Lee KB, Leong KW.

Nano Lett. 2019 Mar 13;19(3):1701-1705. doi: 10.1021/acs.nanolett.8b04697. Epub 2019 Feb 21.

PMID:
30773888
2.

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds.

Sheets KT, Bagó JR, Paulk IL, Hingtgen SD.

J Vis Exp. 2018 Jul 16;(137). doi: 10.3791/57452.

3.

Delivery of Cytotoxic Mesenchymal Stem Cells with Biodegradable Scaffolds for Treatment of Postoperative Brain Cancer.

Sheets KT, Bagó JR, Hingtgen SD.

Methods Mol Biol. 2018;1831:49-58. doi: 10.1007/978-1-4939-8661-3_5.

PMID:
30051424
4.

Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection.

Okolie O, Irvin DM, Bago JR, Sheets K, Satterlee A, Carey-Ewend AG, Lettry V, Dumitru R, Elton S, Ewend MG, Miller CR, Hingtgen SD.

PLoS One. 2018 Jul 10;13(7):e0198596. doi: 10.1371/journal.pone.0198596. eCollection 2018.

5.

Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection.

Graham-Gurysh E, Moore KM, Satterlee AB, Sheets KT, Lin FC, Bachelder EM, Miller CR, Hingtgen SD, Ainslie KM.

Mol Pharm. 2018 Mar 5;15(3):1309-1318. doi: 10.1021/acs.molpharmaceut.7b01114. Epub 2018 Feb 2.

6.

Tumor-homing cytotoxic human induced neural stem cells for cancer therapy.

Bagó JR, Okolie O, Dumitru R, Ewend MG, Parker JS, Werff RV, Underhill TM, Schmid RS, Miller CR, Hingtgen SD.

Sci Transl Med. 2017 Feb 1;9(375). pii: eaah6510. doi: 10.1126/scitranslmed.aah6510.

PMID:
28148846
7.

Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model.

Okolie O, Bago JR, Schmid RS, Irvin DM, Bash RE, Miller CR, Hingtgen SD.

Neuro Oncol. 2016 Dec;18(12):1622-1633. Epub 2016 Jun 13.

8.

Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma.

Bagó JR, Pegna GJ, Okolie O, Mohiti-Asli M, Loboa EG, Hingtgen SD.

Biomaterials. 2016 Jun;90:116-25. doi: 10.1016/j.biomaterials.2016.03.008. Epub 2016 Mar 9.

9.

Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma.

Bagó JR, Alfonso-Pecchio A, Okolie O, Dumitru R, Rinkenbaugh A, Baldwin AS, Miller CR, Magness ST, Hingtgen SD.

Nat Commun. 2016 Feb 2;7:10593. doi: 10.1038/ncomms10593.

10.

Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer.

Bagó JR, Pegna GJ, Okolie O, Hingtgen SD.

Biomaterials. 2016 Apr;84:42-53. doi: 10.1016/j.biomaterials.2016.01.007. Epub 2016 Jan 6.

11.

Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells.

Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, Inskoe E, Piroyan A, Sokolsky M, Okolie O, Hingtgen SD, Kabanov AV, Batrakova EV.

Nanomedicine. 2016 Apr;12(3):655-664. doi: 10.1016/j.nano.2015.10.012. Epub 2015 Nov 14.

12.

Neural stem cell therapy for cancer.

Bagó JR, Sheets KT, Hingtgen SD.

Methods. 2016 Apr 15;99:37-43. doi: 10.1016/j.ymeth.2015.08.013. Epub 2015 Aug 24. Review.

13.

Engineering toxin-resistant therapeutic stem cells to treat brain tumors.

Stuckey DW, Hingtgen SD, Karakas N, Rich BE, Shah K.

Stem Cells. 2015 Feb;33(2):589-600. doi: 10.1002/stem.1874.

14.

Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins.

Klyachko NL, Haney MJ, Zhao Y, Manickam DS, Mahajan V, Suresh P, Hingtgen SD, Mosley RL, Gendelman HE, Kabanov AV, Batrakova EV.

Nanomedicine (Lond). 2014 Jul;9(9):1403-22. doi: 10.2217/nnm.13.115. Epub 2013 Nov 18.

15.

Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases.

Haney MJ, Zhao Y, Harrison EB, Mahajan V, Ahmed S, He Z, Suresh P, Hingtgen SD, Klyachko NL, Mosley RL, Gendelman HE, Kabanov AV, Batrakova EV.

PLoS One. 2013 Apr 19;8(4):e61852. doi: 10.1371/journal.pone.0061852. Print 2013.

16.

A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy.

Hingtgen SD, Kasmieh R, van de Water J, Weissleder R, Shah K.

Stem Cells. 2010 Apr;28(4):832-41. doi: 10.1002/stem.313.

17.

Superoxide scavenging and Akt inhibition in myocardium ameliorate pressure overload-induced NF-κB activation and cardiac hypertrophy.

Hingtgen SD, Li Z, Kutschke W, Tian X, Sharma RV, Davisson RL.

Physiol Genomics. 2010 Apr 1;41(2):127-36. doi: 10.1152/physiolgenomics.00202.2009. Epub 2010 Jan 26.

18.

Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy.

Hingtgen SD, Tian X, Yang J, Dunlay SM, Peek AS, Wu Y, Sharma RV, Engelhardt JF, Davisson RL.

Physiol Genomics. 2006 Aug 16;26(3):180-91. Epub 2006 May 2.

PMID:
16670255
19.

Ganglionic action of angiotensin contributes to sympathetic activity in renin-angiotensinogen transgenic mice.

Ma X, Sigmund CD, Hingtgen SD, Tian X, Davisson RL, Abboud FM, Chapleau MW.

Hypertension. 2004 Feb;43(2):312-6. Epub 2003 Dec 29.

PMID:
14699002
20.

Gene therapeutic approaches to oxidative stress-induced cardiac disease: principles, progress, and prospects.

Hingtgen SD, Davisson RL.

Antioxid Redox Signal. 2001 Jun;3(3):433-49. Review.

PMID:
11491655

Supplemental Content

Loading ...
Support Center